Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
G. L. Andriole(Washington University in St. Louis), Paul A. Kvale(Henry Ford Health System), Grant Izmirlian(National Institutes of Health), Ann W. Hsing(Stanford University), E. David Crawford(University of California San Diego), Philip C. Prorok(National Cancer Institute), John K. Gohagan(National Institutes of Health), Timothy R. Church(University of Minnesota), Paul F. Pinsky(National Cancer Institute), Andrea Miller(Georgetown University), Joel L. Weissfeld(University of Pittsburgh), Claudine Isaacs(Georgetown University), Saundra S. Buys(University of Utah), Mona N. Fouad(University of North Texas), Lance Yokochi(National Institutes of Health), Lawrence R. Ragard(Westat (United States)), David Chia(University of California, Los Angeles), Jonathan D. Clapp(National Institutes of Health), Robert L. Grubb(Washington University in St. Louis), Douglas J. Reding(Ascension), Joshua Rathmell(Georgetown University), B S Kramer(Unknown), Barbara O’Brien(National Institutes of Health), T. Riley(Georgetown University)
Cited by 1,125
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k